TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board

A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership

Vancouver, British Columbia–(Newsfile Corp. – December 10, 2025) – TempraMed Technologies Ltd. (CSE: VIVI) (“TempraMed” or the “Company“), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr. Lutz Heinemann, one of the world’s foremost diabetes researchers, to its Scientific Advisory Board. His appointment further enhances TempraMed’s scientific foundation as the Company expands its portfolio of next-generation thermal-stability technologies for temperature-sensitive medications.

Prof. Heinemann is internationally recognized for pioneering work that bridges insulin pharmacology, diabetes technology, and drug-stability science. As co-founder of the Profil Institute for Metabolic Research and former Managing Editor of the Journal of Diabetes Science and Technology, he has played a central role in advancing insulin kinetics, continuous glucose monitoring (CGM), artificial pancreas systems, and the clinical translation of new diabetes technologies.

Beyond device innovation, Prof. Heinemann has published foundational research demonstrating the critical impact of temperature on insulin and other peptide-based medications, highlighting how improper storage outside the cold chain can degrade potency, reduce therapeutic effectiveness, and compromise patient safety. His dual expertise-deep scientific understanding paired with real-world medication-handling insights-positions him as a global authority on the clinical implications of thermal instability.

“As a researcher who has spent decades investigating how temperature fluctuations impact the stability and safety of insulin and other injectable medications, I have seen firsthand how real-world storage conditions can jeopardize treatment outcomes. TempraMed’s technologies offer a scientifically sound and practical solution to this long-standing challenge. I am pleased to join the advisory board and support their mission to improve medication safety and reliability for patients around the world,” commented Prof. Dr. Lutz Heinemann.

Ron Nagar, CEO, TempraMed, said: “We are privileged to welcome Prof. Heinemann to TempraMed’s Scientific Advisory Board. His contributions to diabetes research have shaped global understanding of insulin behavior, technology innovation, and medication stability. Having his guidance is invaluable as we continue developing solutions that improve the daily lives of people managing chronic diseases by ensuring their medications remain safe, effective, and reliable-wherever life takes them. We look forward to working with Prof Heinemann, as his guidance and advice will be invaluable as we continue to advance our global offering.”

Strategic Significance for TempraMed

Prof. Heinemann’s extensive background enhances TempraMed’s capabilities across several high-priority domains:

• Global partnerships: Strengthening TempraMed’s engagement with potential partners; pharma, payors, clinical networks, digital-health platforms, and diabetes-technology leaders to drive collaborative innovation, scale distribution, and support broad market adoption.
• Market access and education: Helping shape medical-professional and patient-facing guidance about temperature-sensitive medication handling.
• Clinical validation and evidence generation: Supporting TempraMed’s scientific studies on medication stability, adherence, and clinical-use cases.
• Technology evaluation: Providing expert insight into device functionality, performance requirements, and integration with digital-health ecosystems.

About TempraMed Technologies Ltd.

TempraMed Technologies Ltd. is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, space-grade thermal insulation devices that work 24/7 without batteries or external power. With a proven product line including VIVI Cap and VIVI Epi, and a smart technology platform on the horizon, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. Headquartered in Israel with operations in North America, Europe, and Asia, TempraMed is advancing the future of medication protection and adherence.

Cautionary Statements

This press release contains “forward-looking statements or information.” Forward-looking statements can be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Examples of forward-looking statements in this press release include statements made regarding information about future plans, expectations and objectives of the Company overall.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company may not actually achieve its plans, projections, or expectations. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the adequacy of our cash flow and earnings, the availability of future financing and/or credit, developments and changes in laws and regulations, consumer sentiment towards the Company’s products, failure of counterparties to perform their contractual obligations, government regulations, competition, loss of key employees and consultants, and general economic, market or business conditions, the impact of technology and social changes on the products and industry.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277598